Literature DB >> 22095874

Contribution of individual PKC isoforms to breast cancer progression.

Alejandro J Urtreger1, Marcelo G Kazanietz, Elisa D Bal de Kier Joffé.   

Abstract

The protein kinase C (PKC) family of serine/threonine kinases has been intensively studied in cancer since their discovery as major receptors for the tumor-promoting phorbol esters. The contribution of each individual PKC isozyme to malignant transformation is only partially understood, but it is clear that each PKC plays different role in cancer progression. PKC deregulation is a common phenomenon observed in breast cancer, and PKC expression and localization are usually dynamically regulated during mammary gland differentiation and involution. In fact, the overexpression of several PKCs has been reported in malignant human breast tissue and breast cancer cell lines. In this review, we summarize the knowledge available on the specific roles of PKC isoforms in the development, progression, and metastatic dissemination of mammary cancer. We also discuss the role of PKC isoforms as therapeutic targets, and their potential as markers for prognosis or treatment response.
Copyright © 2011 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095874     DOI: 10.1002/iub.574

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  34 in total

1.  Intracellular Delivery of Anti-pPKCθ (Thr538) via Protein Transduction Domain Mimics for Immunomodulation.

Authors:  E Ilker Ozay; Gabriela Gonzalez-Perez; Joe A Torres; Jyothi Vijayaraghavan; Rebecca Lawlor; Heather L Sherman; Daniel T Garrigan; Amy S Burnside; Barbara A Osborne; Gregory N Tew; Lisa M Minter
Journal:  Mol Ther       Date:  2016-09-16       Impact factor: 11.454

2.  MicroRNA-200b suppresses arsenic-transformed cell migration by targeting protein kinase Cα and Wnt5b-protein kinase Cα positive feedback loop and inhibiting Rac1 activation.

Authors:  Zhishan Wang; Brock Humphries; Hua Xiao; Yiguo Jiang; Chengfeng Yang
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

3.  MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα.

Authors:  Yuanchuan Wang; Xiaohong Yin; Long Zhao; Shun Li; Jie Duan; Renzhao Kuang; Junwei Duan
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

4.  PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Authors:  A Paul; S Gunewardena; S R Stecklein; B Saha; N Parelkar; M Danley; G Rajendran; P Home; S Ray; I Jokar; G A Vielhauer; R A Jensen; O Tawfik; S Paul
Journal:  Cell Death Differ       Date:  2014-05-02       Impact factor: 15.828

5.  High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.

Authors:  Norbert Nass; Sarah Walter; Dörthe Jechorek; Christine Weissenborn; Atanas Ignatov; Johannes Haybaeck; Saadettin Sel; Thomas Kalinski
Journal:  Virchows Arch       Date:  2017-05-24       Impact factor: 4.064

6.  Activation of atypical protein kinase C by sphingosine 1-phosphate revealed by an aPKC-specific activity reporter.

Authors:  Taketoshi Kajimoto; Alisha D Caliman; Irene S Tobias; Taro Okada; Caila A Pilo; An-Angela N Van; J Andrew McCammon; Shun-Ichi Nakamura; Alexandra C Newton
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

7.  Schwann cells induce cancer cell dispersion and invasion.

Authors:  Sylvie Deborde; Tatiana Omelchenko; Anna Lyubchik; Yi Zhou; Shizhi He; William F McNamara; Natalya Chernichenko; Sei-Young Lee; Fernando Barajas; Chun-Hao Chen; Richard L Bakst; Efsevia Vakiani; Shuangba He; Alan Hall; Richard J Wong
Journal:  J Clin Invest       Date:  2016-03-21       Impact factor: 14.808

8.  Protein kinase C mediates enterohemorrhagic Escherichia coli O157:H7-induced attaching and effacing lesions.

Authors:  Grace Shen-Tu; Hyunhee Kim; Mingyao Liu; Kathene C Johnson-Henry; Philip M Sherman
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

9.  Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

Authors:  X Chen; Q Wu; L Tan; D Porter; M J Jager; C Emery; B C Bastian
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

10.  A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.

Authors:  Tameka A Bailey; Haitao Luan; Eric Tom; Timothy Alan Bielecki; Bhopal Mohapatra; Gulzar Ahmad; Manju George; David L Kelly; Amarnath Natarajan; Srikumar M Raja; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.